Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 14
Commentary
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 3,149 | Dovepress* | 2,937+ | 60 | 2,997 | |
| PubMed Central* | 212 | 109 | 321 | ||
| Totals | 3,149 | 169 | 3,318 | ||
| *Since 22 June 2023 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 13 | 0 | 0 | 0 | 5 | 8 |
View citations on PubMed Central and Google Scholar